Antigen-specific immunotherapy against allergic rhinitis: The state of the art

Allergology International

Volumn 59, Issue 1, 2010, Pages 21-31

  Fujimura, Takashi ^a,b   Okamoto, Yoshitaka ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

Author keywords

Allergic rhinitis; Biomarker; Immunotherapy; Pollinosis; Regulatory t cell

Indexed keywords

ALUMINUM HYDROXIDE; CD150 ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; LATEX; LEPTIN; POLLEN ANTIGEN; RECOMBINANT ALLERGEN; RUBBER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADIPOCYTE; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTIGEN SPECIFICITY IMMUNOTHERAPY; APOPTOSIS; ASTHMA; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOTHERAPY; IN VITRO STUDY; INGUINAL LYMPH NODE; INSECT STING; JAPANESE CEDAR; LYMPH NODE; LYMPHOCYTE ACTIVATION; MAST CELL DEGRANULATION; MOUTH EDEMA; MOUTH MUCOSA; NONHUMAN; ORAL PRURITUS; PERENNIAL RYEGRASS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN MICROARRAY; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SNEEZING; SWALLOWING; T LYMPHOCYTE ACTIVATION; THROAT IRRITATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPREGULATION; URTICARIA; VIRUS INFECTION; VISUAL ANALOG SCALE;

EID: 77949727803     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.09-RAI-0151     Document Type: Review

References (75)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.
2. Baba K, Nakae K. [Epidemiology of nasal allergy through Japan in 2008]. Prog Med 2008;28:2001-12(in Japanese).
3. Grote M, Vrtala S, Niederberger V, Wiermann R, Valenta R, Reichelt R. Release of allergen-bearing cytoplasm from hydrated pollen: a mechanism common to a variety of grass (Poaceae) species revealed by electron microscopy. J Allergy Clin Immunol 2001;108:109-15.
4. Maeda Y, Akiyama K, Shida T. A clinical study of Japanese cedar (Cryptomeria japonica) pollen-induced asthma. Allergol Int 2008;57:413-7.
5. Plotz SG, Traidl-Hoffmann C, Feussner I et al. Chemotaxis and activation of human peripheral blood eosinophils induced by pollen-associated lipid mediators. J Allergy Clin Immunol 2004;113:1152-60.
6. Traidl-Hoffmann C, Kasche A, Jakob T et al. Lipid mediators from pollen act as chemoattractants and activators of polymorphonuclear granulocytes. J Allergy Clin Immunol 2002;109:831-8.
7. Gutermuth J, Bewersdorff M, Traidl-Hoffmann C et al. Immunomodulatory effects of aqueous birch pollen extracts and phytoprostanes on primary immune responses in vivo. J Allergy Clin Immunol 2007;120:293-9.
8. Boldogh I, Bacsi A, Choudhury BK et al. ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. J Clin Invest 2005;115:2169-79.
9. Dharajiya N, Choudhury BK, Bacsi A, Boldogh I, Alam R, Sur S. Inhibiting pollen reduced nicotinamide adenine dinucleotide phosphate oxidase-induced signal by intrapulmonary administration of antioxidants blocks allergic allergic airway inflammation. J Allergy Clin Immunol 2007;119:646-53.
10. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-7.
11. Jauregui I, Mullol J, Davila I et al. Allergic rhinitis and school performance. J Investig Allergol Clin Immunol 2009;19:32-9.
12. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;177:1572-3.
13. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761-71.
14. American Academy of Allergy, Asthma and Immunology. The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 1997;99:583-6.
15. Canonica GW, Baena-Cagnani CE, Bousquet J et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24.
16. van Ree R, Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310-26.
17. Salcedo G, Diaz-Perales A, Sanchez-Monge R. The role of plant panallergens in sensitization to natural rubber latex. Curr Opin Allergy Clin Immunol 2001;1:177-83.
18. Harwanegg C, Laffer S, Hiller R et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy 2003;33:7-13.
19. Deinhofer K, Sevcik H, Balic N et al. Microarrayed allergens for IgE profiling. Methods 2004;32:249-54.
20. Pittner G, Vrtala S, Thomas WR et al. Componentresolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603.
21. Bhalla PL, Singh MB. Biotechnology-based allergy diagnosis and vaccination. Trends Biotechnol 2008;26:153-61.
22. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-13.
23. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-60.
24. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009;8:645-60.
25. Zoss A, Koch C, Hirose R. Alum-ragweed precipitate: preparation and clinical investigation; preliminary report. J Allergy 1937;8:329-35.
26. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:81-6.
27. Klunker S, Saggar LR, Seyfert-Margolis V et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120:688-95.
28. Calderon M, Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax. Ther Clin Risk Manag 2008;4:1255-60.
29. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236-7.
30. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006;61:1235.
31. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-8.
32. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4.
33. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 2009;124:378-9.
34. Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849-54.
35. Panzner P, Petras M, Sykora T, Lesna I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 2008;102:1296-304.
36. Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122-9.
37. Bagnasco M, Passalacqua G, Villa G et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54-60.
38. Passalacqua G, Villa G, Altrinetti V et al. Sublingual swallow or spit? Allergy 2001;56:578.
39. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007;62:958-61.
40. Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401-8.
41. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-35.
42. Johansen P, Haffner AC, Koch F et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005;35:568-74.
43. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-12.
44. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003;33:1171-4.
45. Lima MT, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507-14.
46. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
47. Horiguchi S, Okamoto Y, Yonekura S et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol 2008;146:76-84.
48. Ciprandi G, Continia P, Fenoglio D et al. Relationship between soluble HLA-G and HLA-A, -B, -C serum levels, and interferon-gamma production after sublingual immunotherapy in patients with allergic rhinitis. Hum Immunol 2008;69:409-13.
49. Ciprandi G, Contini P, Pistorio A, Murdaca G, Puppo F. Sublingual immunotherapy reduces soluble HLA-G and HLA-A, -B, -C serum levels in patients with allergic rhinitis. Int Immunopharmacol 2009;9:253-7.
50. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
51. De Rosa V, Procaccini C, Cali G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007;26:241-55.
52. Ciprandi G, De Amici M, Murdaca G, Filaci G, Fenoglio D, Marseglia GL. Adipokines and sublingual immunotherapy: preliminary report. Hum Immunol 2009;70:73-8.
53. Ciprandi G, De Amici M, Tosca M, Negrini S, Murdaca G, Marseglia GL. Two year sublingual immunotherapy affects serum leptin. Int Immunopharmacol 2009;9:1244-6.
54. Okano M, Otsuki N, Azuma M et al. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis. Clin Exp Allergy 2008;38:1891-900.
55. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005;136:134-41.
56. Savolainen J, Nieminen K, Laaksonen K et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007;62:949-53.
57. Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol. Epub 2009 Jun 29.
58. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J ExpMed 2004;199:1567-75.
59. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-14.
60. Ciprandi G, Fenoglio D, Cirillo I et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95:38-44.
61. Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca MA. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006;6:1370-3.
62. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13.
63. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:1184-90.
64. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467-72.
65. Pereira-Santos MC, Baptista AP, Melo A et al. Expansion of circulating Foxp3+CD25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008;38:291-7.
66. Gri G, Piconese S, Frossi B et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008;29:771-81.
67. Ohkawara Y, Lim KG, Xing Z et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 1996;97:1761-6.
68. Fujisawa T, Nagao M, Hiraguchi Y et al. Biomarkers for allergen immunotherapy in cedar pollinosis. Allergol Int 2009;58:163-70.
69. Okubo K, Gotoh M, Fujieda S et al. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int 2008;57:265-75.
70. Hirahara K, Tatsuta T, Takatori T et al. Preclinical evaluation of an immunotherapeutic peptide comprising 7 Tcell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001;108:94-100.
71. Yamanaka K, Yuta A, Kakeda M et al. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009;124:842-5.
72. Yang L, Suzuki K, Hirose S, Wakasa Y, Takaiwa F. Development of transgenic rice seed accumulating a major Japanese cedar pollen allergen (Cry j 1) structurally disrupted for oral immunotherapy. Plant Biotechnol J 2007;5:815-26.
73. Takagi H, Hiroi T, Yang L et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A 2005;102: 17525-30.
74. Ishii Y. [Allergen-specific immunotherapy utilizing mechanisms for immune regulation]. Nihon Rinsho Meneki Gakkai Kaishi 2008;31:392-8(in Japanese).
75. Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002;16:1301-3.